Complex alternative splicing of the hKLK3 gene coding for the tumor marker PSA (prostate-specific-antigen)

被引:29
作者
Heuzé-Vourc'h, N [1 ]
Leblond, V [1 ]
Courty, Y [1 ]
机构
[1] Univ Tours, EMIU 0010, Lab Enzymol & Chim Prot, F-37032 Tours, France
来源
EUROPEAN JOURNAL OF BIOCHEMISTRY | 2003年 / 270卷 / 04期
关键词
alternative mRNA; PSA variant; tumor marker; prostate cancer;
D O I
10.1046/j.1432-1033.2003.03425.x
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
PSA (prostate-specific antigen), the most useful serum marker for prostate cancer, is encoded by the hKLK3 gene and is present in the serum as a mixture of several molecular species. This work was performed to identify the hKLK3 transcripts in order to determine how many proteins resembling PSA are synthesized from the hKLK3 gene and secreted in blood. Combined Northern blotting, molecular cloning and database searching showed that the hKLK3 gene produces at least 15 transcripts ranging in size from 0.7 to 6.1 kb. Polysomal distribution analysis revealed that the transcripts shorter than 3.1 kb are efficiently translated in prostate cell line. A total of 12 hKLK3 transcripts have been completely or partially cloned. They result from alternative splicing or/and alternative polyadenylation involving complex regulation. They code for eight proteins: PSA, a truncated form of PSA (PSA-Tr), five PSA variants (PSA-RPs) and one protein (PSA-LM) unrelated to PSA. Using a specific antibody, we detected the PSA-RP2 variant in prostate tissue. All the variants share the same signal peptide and could contribute to the diversity of hKLK3 proteins in prostate fluid and blood.
引用
收藏
页码:706 / 714
页数:9
相关论文
共 40 条
[1]   Exonic splicing enhancers: mechanism of action, diversity and role in human genetic diseases [J].
Blencowe, BJ .
TRENDS IN BIOCHEMICAL SCIENCES, 2000, 25 (03) :106-110
[2]   Analysis of canonical and non-canonical splice sites in mammalian genomes [J].
Burset, M ;
Seledtsov, IA ;
Solovyev, VV .
NUCLEIC ACIDS RESEARCH, 2000, 28 (21) :4364-4375
[3]   A 5′ splice site-proximal enhancer binds SF1 and activates exon bridging of a microexon [J].
Carlo, T ;
Sierra, R ;
Berget, SM .
MOLECULAR AND CELLULAR BIOLOGY, 2000, 20 (11) :3988-3995
[4]   Prostate-specific antigen best practice policy - part I: Early detection and diagnosis of prostate cancer [J].
Carroll, P ;
Coley, C ;
McLeod, D ;
Schellhammer, P ;
Sweat, G ;
Wasson, J ;
Zietman, A ;
Thompson, I .
UROLOGY, 2001, 57 (02) :217-224
[5]   Prostate-specific antigen best practice policy - part II: Prostate cancer staging and post-treatment follow-up [J].
Carroll, P ;
Coley, C ;
McLeod, D ;
Schellhammer, P ;
Sweat, G ;
Wasson, J ;
Zietman, A ;
Thompson, I .
UROLOGY, 2001, 57 (02) :225-229
[6]   BIOLOGICAL EFFECTS OF PROSTATE-SPECIFIC ANTIGEN AS AN INSULIN-LIKE GROWTH-FACTOR BINDING PROTEIN-3 PROTEASE [J].
COHEN, P ;
PEEHL, DM ;
GRAVES, HCB ;
ROSENFELD, RG .
JOURNAL OF ENDOCRINOLOGY, 1994, 142 (03) :407-415
[7]   Unusual alternative splicing within the human kallikrein genes KLK2 and KLK3 gives rise to novel prostate-specific proteins [J].
David, A ;
Mabjeesh, N ;
Azar, I ;
Biton, S ;
Engel, S ;
Bernstein, J ;
Romano, J ;
Avidor, Y ;
Waks, T ;
Eshhar, Z ;
Langer, SZ ;
Lifschitz-Mercer, B ;
Matzkin, H ;
Rotman, G ;
Topoirik, A ;
Savitsky, K ;
Mintz, L .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (20) :18084-18090
[8]   The new human kallikrein gene family: Implications in carcinogenesis [J].
Diamandis, EP ;
Yousef, GM ;
Luo, LY ;
Magklara, A ;
Obiezu, CV .
TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2000, 11 (02) :54-60
[9]   Antiangiogenic activity of prostate-specific antigen [J].
Fortier, AH ;
Nelson, BJ ;
Grella, DK ;
Holaday, JW .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1999, 91 (19) :1635-1640
[10]   Co-transcriptional splicing of pre-messenger RNAs: considerations for the mechanism of alternative splicing [J].
Goldstrohm, AC ;
Greenleaf, AL ;
Garcia-Blanco, MA .
GENE, 2001, 277 (1-2) :31-47